Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group

Andrea Casadei Gardini, Emanuela Scarpi, Giorgia Marisi, Francesco Giuseppe Foschi, Gabriele Donati, Emanuela Giampalma, Luca Faloppi, Mario Scartozzi, Nicola Silvestris, Marcello Bisulli, J. Corbelli, Andrea Gardini, Giuliano La Barba, Luigi Veneroni, Stefano Tamberi, Stefano Cascinu, Giovanni Luca Paolo Frassineti

Research output: Contribution to journalArticle

Abstract

Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway and appears to be a generalized effect of this class of agent. We investigated the phenomenon in 61 patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib. Blood pressure and plasma electrolytes were measured on days 1 and 15 of the treatment. Patients with sorafenib-induced HTN had a better outcome than those without HTN (disease control rate: 63.4% vs. 17.2% (p=0.001); progression-free survival 6.0 months (95% CI 3.2-10.1) vs. 2.5 months (95% CI 1.9-2.6) (p

Original languageEnglish
Pages (from-to)15243-15251
Number of pages9
JournalOncotarget
Volume7
Issue number12
DOIs
Publication statusPublished - Mar 22 2016

Keywords

  • Hepatocellular carcinoma
  • Hypertension
  • Liver cancer
  • Predictive biomarker
  • Sorafenib

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group'. Together they form a unique fingerprint.

  • Cite this